Navigation Links
Cytopia Presentation on VDA CYT997 at AACR Conference
Date:4/15/2009

MELBOURNE, Australia, April 15 /PRNewswire/ -- Cytopia Limited (ASX: CYT) announced that it will present data on its anticancer vascular disrupting agent (VDA) CYT997 at the forthcoming 100th Annual Meeting of the American Association for Cancer Research, in Denver, Colorado, USA.

Dr David Segal, Principal Scientist at Cytopia, will be presenting the poster in the Late-Breaking Research: Experimental and Molecular Therapeutics 2 poster session on Tuesday, April 21, 2009 from 8:00 AM to 2:00 PM (US MDT), Hall BF, Poster Section 26, Poster Board 18.

The poster, entitled CYT997: Preclinical studies on the antivascular effects and mode of action of a Phase II vascular disrupting agent outlines extensive preclinical data for CYT997 which is currently in Phase II clinical studies. Data for CYT997 in a panel of in vitro and in vivo assays will be shown clearly demonstrating the potent antivascular and cytotoxic effects of the compound.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and San Francisco, USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialed in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009.

Website: www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research
2. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
3. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
4. Cytopia and Other Progen Shareholders Maintain Call for Meeting
5. Cytopia Letter to Progen Shareholders
6. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
7. Strategic Diagnostics Updates Roth Conference Presentation Time
8. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
9. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
10. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
11. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 Novogene ... services and solutions with cutting edge next-generation sequencing (NGS) ... a USD $75 Million [515 Million RMB] B round ... Capital Management ( Shenzhen ) Co., Ltd. ... Innovation") and Shanghai Sigma Square Investment Center LP ("Sigma ...
(Date:11/30/2016)... 30, 2016   Merck , a leading science ... into a set of agreements with Evotec AG, whereby ... of genetic reagents such as CRISPR and shRNA libraries. ... offers an accelerated pathway to explore and identify new ... identification of new targets, a process that can be ...
(Date:11/30/2016)... NC (PRWEB) , ... November 30, 2016 , ... ... engaged in the development of a new orally administered treatment for Alzheimer’s disease ... neuroimaging results of a Phase 2a clinical trial of T3D-959 in mild to ...
(Date:11/30/2016)... ... 30, 2016 , ... ProMIS Neurosciences (“ProMIS” or the “Company”), ... today announced that all five of its validated monoclonal antibody (mAb) therapeutic candidates ... prion-like forms of Amyloid beta (Aß) in vitro. , “We previously demonstrated that ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
Breaking Biology News(10 mins):